Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Type 2 Diabetes, Type II Diabetes Mellit...
Phase NA
Enrollment 216
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Only 2% of Americans meet the recommended levels of whole grain consumption, despite its association with reduced risk of type 2 diabetes. This study aims to assess if consumers with prediabetes or type 2 diabetes can be encouraged to switch from buying refined grain products to whole grain products when shopping for groceries online. The study will use personalized marketing strategies, with or without discounts which adjust based on purchasing behavior, to promote whole grain consumption.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Marketing Nudges Only — Marketing nudges encouraging whole grain purchasing, including displaying whole grains (e.g., whole wheat bread, brown rice) at the top of the study's online grocery store, featuring whole grain banner displays, and offering product swaps to highlight whole grain alternatives
  • Behavioral: Marketing Nudges + Dynamically Adapted Financial Incentives — Marketing nudges encouraging whole grain purchasing, including displaying whole grains (e.g., whole wheat bread, brown rice) at the top of the study's online grocery store, featuring whole grain banner displays, and offering product swaps to highlight whole grain alternatives, plus personalized financial incentives with individual incentive amounts optimized weekly based on prior whole grain purchasing behavior and engagement

Primary Outcomes

  • Change in calories purchased from products that are majority whole grains over time (18 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-14
Completion: 2027-02-16
Eligibility
Age: 45 Years and older
Sex: ALL
Volunteers: false
Enrollment: 216 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Pennsylvania
Collaborators: National Institute on Aging (NIA), American Heart Association
Principal Investigators:
  • Sophia V Hua, PhD, MPH (PRINCIPAL_INVESTIGATOR) - Department of Medical Ethics and Health Policy, Perelman School of Medicine
Contact Information
Study Contact:
Emily Dzieniszewski, MPH
215-898-0954
Emily.Dzieniszewski@Pennmedicine.upenn.edu
Julianna Catania, MPH
julianna.catania@pennmedicine.upenn.edu
Emily Dzieniszewski, MPH
215-898-0954
Emily.Dzieniszewski@Pennmedicine.upenn.edu
University of Pennsylvania
Interventions
  • Behavioral: Marketing Nudges Only — Marketing nudges encouraging whole grain purchasing, including displaying whole grains (e.g., whole wheat bread, brown rice) at the top of the study's online grocery store, featuring whole grain banner displays, and offering product swaps to highlight whole grain alternatives
  • Behavioral: Marketing Nudges + Dynamically Adapted Financial Incentives — Marketing nudges encouraging whole grain purchasing, including displaying whole grains (e.g., whole wheat bread, brown rice) at the top of the study's online grocery store, featuring whole grain banner displays, and offering product swaps to highlight whole grain alternatives, plus personalized financial incentives with individual incentive amounts optimized weekly based on prior whole grain purchasing behavior and engagement
Study Locations (1 sites)
University of Pennsylvania, Philadelphia, Pennsylvania 19104 United States
Eligibility Criteria
Inclusion Criteria: * Age 45 - 70 years. * Able to provide consent. * Resident of Philadelphia, Bucks, Delaware, Chester, or Montgomery Counties in Pennsylvania. * Consume \<5 servings of whole grains per day. * Use online grocery shopping at least once per month. * Have access to a credit or debit card to pay for groceries purchased. * Have reliable internet access. * Speak English. * Penn Medicine patient diagnosed with prediabetes or diabetes (identified using ICD-10 codes R73.03, E11). Exclusion Criteria: * Does not meet all the inclusion criteria. * Not able to speak English. * Not able to provide consent.
Conditions Solid Tumor, Solid Tumor, Adult
Phase NA
Enrollment 125
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to improve ways of providing mental health support to Spanish-speaking Latino participants who have cancer and experience depression, insomnia, and fatigue. Investigators will test a special mental health intervention called DESCANSO/REST (Depresión/Depressed Mood, Cansancio/Fatigue, and Sueño/Sleep). The intervention can be delivered through telehealth.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: DESCANSO/Depresión/Depressed Mood, Cansancio/Fatigue, and Sueño/Sleep; Rest in English — DESCANSO (Depresión/Depressed Mood, Cansancio/Fatigue, and Sueño/Sleep; Rest in English)

Primary Outcomes

  • Number of participants who complete at least 5 DESCANSO sessions (Up to 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-23
Completion: 2030-07-31
Eligibility
Age: 21 Years and older
Sex: ALL
Volunteers: true
Enrollment: 125 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Principal Investigators:
  • Devika Jutagir, PhD (PRINCIPAL_INVESTIGATOR) - Memorial Sloan Kettering Cancer Center
Contact Information
Study Contact:
Devika Jutagir, PhD
646-888-8361
jutagird@mskcc.org
Victoria Blinder, MD
646-888-4808
blinderv@mskcc.org
Devika Jutagir, PhD
646-888-8361
Memorial Sloan Kettering Cancer Center Basking Ridge (Limited Protocol Activities)
Interventions
  • Behavioral: DESCANSO/Depresión/Depressed Mood, Cansancio/Fatigue, and Sueño/Sleep; Rest in English — DESCANSO (Depresión/Depressed Mood, Cansancio/Fatigue, and Sueño/Sleep; Rest in English)
Study Locations (7 sites)
Memorial Sloan Kettering Cancer Center Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey 07920 United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey 07748 United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey 07645 United States
Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity), Commack, New York 11725 United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York 10604 United States
Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States
Memorial Sloan Kettering Nassau (Limited Protocol Activites), Rockville Centre, New York 11553 United States
Eligibility Criteria
Provider Eligibility Criteria: Participant eligibility will be determined by a self-report screener. Inclusion Criteria Self-Report Criteria * Mental health provider * Treats Latino cancer patients and/or survivors * Has at least 3 years of clinical experience providing psychosocial services to cancer patients and/or survivors * Able to read Spanish determined by the question: "Can you read in Spanish? Yes/No" Patient Eligibility Criteria: A patient cannot be considered eligible for this study unless ALL of the following conditions are met. Participant eligibility will be determined by an initial EMR review followed by a self-report screener. Inclusion Criteria EMR Criteria * Documentation of Disease o Pathologically confirmed solid tumor cancer (either most recent or new diagnosis) * Definition of Disease \[or Measurable Disease\] o Diagnosed with stages I, II, or III * Prior Treatment * Currently undergoing systemic therapy (chemotherapy, radiation therapy, and/or immunotherapy) or within the first year following completion of systemic therapy Self-Report Criteria * Age ≥ 21 years * Lives in mainland U.S. or Puerto Rico * Identifies as Latino/a or Hispanic * Reports Spanish as their preferred language * Speaks Spanish "Very well" or "Well" as determined by the question: "How well do you speak Spanish?" * Presence of fatigue and disturbed sleep determined by a score of ≥ 3 on the MD Anderson Symptom Inventory Exclusion Criteria EMR Criteria o In the judgment of the treating physician, protocol investigators, and/or study staff, presence of cognitive impairment (e.g., delirium or dementia) sufficient to preclude meaningful informed consent and/or study participation Self-Report Criteria * History of comorbidities within the last 12 months associated with fatigue and poor sleep, including hypothyroidism or abnormal thyroid function, sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, alcohol or drug abuse * Pregnant or lactating, women only * Presence of suicidal risk determined by any affirmative response on the Columbia-Suicide Severity Rating Scale
Conditions Castration-Resistant Prostate Cancer (CR...
Phase PHASE1, PHASE2
Enrollment 61
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

A Phase 1/2a Dose Escalation and Expansion Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients with Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: 177Lu-BetaBart — BetaBart administered by intravenous (IV) infusion every 6 weeks

Primary Outcomes

  • Recommended dose(s) of 177Lu-BetaBart for future exploration (phase 1) (6 weeks)
  • Incidence of treatment emergent adverse events of 177-Lu-BetaBart (phase 1) (Safety and Tolerability) (6 weeks)
  • To assess the preliminary anti-tumor activity of 177Lu-BetaBart at the RP2D (phase 2a) (Up to 30 weeks)
  • To assess preliminary anti-tumor activity, as defined by biochemical response, in CRPC participants who are treated with 177Lu-BetaBart at the RP2D (phase 2a) (Up to 30 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2026-02-23
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 61 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Radiopharm Theranostics, Ltd
Collaborators: Medpace, Inc.
Contact Information
Study Contact:
Dimitris Voliotis, MD
646-535-5017
dv@radiopharmtheranostics.com
Juli Love
334-305-0024
jlove@alocentclinical.com
Dothan Hematology & Oncology
BAMF Clinical Trials Team
616-330-2735
ResearchClinicalTeam@bamfhealth.com
BAMF Health
Interventions
  • Drug: 177Lu-BetaBart — BetaBart administered by intravenous (IV) infusion every 6 weeks
Study Locations (4 sites)
Dothan Hematology & Oncology, Dothan, Alabama 36303 United States
BAMF Health, Grand Rapids, Michigan 49503 United States
Nebraska Cancer Specialists, Omaha, Nebraska 68130 United States
XCancer, Omaha, Nebraska 68130 United States
Eligibility Criteria
Inclusion Criteria: 1. Willing and able to provide informed consent prior to start of any study procedures and assessments and must be willing to comply with all study procedures. 2. Participants ≥ 18 years of age. 3. Participants with a documented history of histopathologically confirmed CRPC\*, CRC, NSCLC, SCLC, HNSCC, ovarian cancer, cervical cancer, endometrial cancer, TNBC, or ESCC. (Note: inclusion or exclusion criteria below marked with \* refer to CRPC only, criteria without \* refer to all tumor indications including CRPC) a. \*Progressive CRPC defined as castrate levels of testosterone and progressing by at least one of the following criteria: i. Serum PSA progression consisting of two consecutive increases in PSA measured at least 1 week apart. The minimal baseline value is 2.0 ng/mL. ii. Soft tissue progression defined as a ≥20% increase in the sum of the diameter (short axis for nodal lesions and long axis for non-nodal lesions) of all target lesions based on the smallest sum of the diameter since the previous treatment was started or the appearance of one or more new lesions by computed tomography (CT)/magnetic resonance imaging (MRI). iii. Progression of bone disease defined by Prostate Cancer Working Group 3 (PCWG3) as evaluable disease or new bone lesions by bone scan. iv. Identification of new soft tissue or bone lesions on prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging. b. \*Metastatic disease defined as either or both of the following: i. Documented M1 disease on conventional imaging (CT/MRI of the chest/abdomen/pelvis and/or Technetium 99m \[99mTc\] whole-body bone scan) ii. Identification of bone lesion(s), extra-pelvic soft tissue lesion(s), or visceral metastases on PSMA PET imaging with an FDA-approved imaging agent (e.g., 68Ga-PSMA-11, 18F-DCFPyL, or 18F-rhPSMA-7.3) c. \*Progression following treatment with ADT and at least one ARSI (e.g., enzalutamide, apalutamide, darolutamide, and/or abiraterone acetate). If a participant is currently on ADT, they should continue ADT for the duration of their participation in the study but will not be permitted to start a new therapy or ADT regimen. If a participant has progressed on an ARSI, they will have the option to remain on the same ARSI or discontinue therapy. If they discontinue the ARSI, a 28-day washout period will be required prior to initiating study intervention. d. Prior definitive and palliative external beam radiation therapy and stereotactic body radiation therapy is allowed. Note: Participants with extended external beam radiation therapy to the axial skeleton, which in the opinion of the Investigator may pose a risk for increased myelotoxicity, will be discussed with the Sponsor to determine eligibility. e. Participants with liver metastases are eligible if they meet the following criteria: i. ≤3 lesions i. All lesions must be ≤2 cm in the short axis ii. SUVmean ≥2 x that of liver parenchyma f. \*Prior treatment with one taxane-based chemotherapy is allowed but not required. A taxane-based chemotherapy is defined as a minimum exposure of two cycles of a taxane chemotherapy. 4. Participants must have documented disease progression during or after their most recent line of anticancer therapy. Participants must be refractory to or intolerant of standard of care therapy or have no standard of care therapy available that is likely to provide clinical benefit. Any number of prior treatment lines are allowed. 5. Must have at least 1 measurable target lesion according to RECIST v1.1. (Note: this does not apply for CRPC) 6. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 7. Participants must have a life expectancy of ≥ 4 months in the opinion of the Investigator. 8. Participants of child-bearing potential (CBP) must have a negative β-hCG test and must not be breastfeeding. Participants of CBP are defined as those who are not surgically sterile or post-menopausal. Participants will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. Participants \< 50 years of age who meet the criteria for post-menopausal status without previous surgical sterilization should be considered for further investigation with luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels to confirm serological post-menopausal status. 9. Participants of CBP must agree to use a highly effective method of contraception during the study and for 6 months after the last dose of 177Lu-BetaBart, as described in Appendix 4. 10. Male participants who are able to father a child must agree to avoid impregnating a partner and to adhere to a highly effective method of contraception during the study and for 6 months after the last dose of 177Lu-BetaBart, as described in Appendix 4. All male participants must agree to not donate sperm during the study and for 6 months after the last dose of 177Lu-BetaBart. 11. Participants who have received prior radiation therapy \>28 days before the first dose of 177Lu-BetaBart are permitted. Documentation of the dates the radiotherapy was received, the cumulative dose, and the absorbed dose to critical organs, if available, should be provided. 12. Participants with previously treated brain metastases are eligible to participate if: * they are neurologically and radiologically stable (no evidence of progression by imaging; same imaging modality \[MRI or CT scan\] must be used for each assessment) for at least 28 days prior to the first dose of 177Lu-BetaBart; and * do not require corticosteroids to treat associated neurological symptoms or if required, are on a stable dose of corticosteroids not exceeding 10 mg/day of prednisone (or equivalent), and * have no history of leptomeningeal disease or spinal cord compression. Exclusion Criteria: 1. History of prior organ transplant. 2. Any other known, active malignancy, except for treated cervical intraepithelial neoplasia, or non-melanoma skin cancer. Participants with a history of malignancies of low recurrence potential who have received curative-intent therapy may be approved on a case-by-case basis in discussion with the Sponsor, if it is determined not to put the participant at an increased risk of adverse drug effects and/or interfere with the integrity of the study outcome. 3. Have any medical condition that would, in the Investigator's judgment, prevent the participant's full participation in the clinical study due to safety concerns or compliance with clinical study procedures such as participants with severe claustrophobia who are unresponsive to oral anxiolytics, participants with low back pain who cannot lie comfortably on an imaging table, participants who are hyperactive or hyperkinetic such that they cannot tolerate lying still for multiple time point imaging procedures, etc. 4. Residual toxicity ≥ Grade 2 from prior anti-cancer therapy (except alopecia and peripheral sensory neuropathy). 5. History of uncontrolled allergic reactions and/or known or expected hypersensitivity to protein therapeutics, 177Lu-BetaBart, or any of its excipients. 6. Inadequate organ functions as reflected in laboratory parameters: * Estimated glomerular filtration rate (eGFR) \< 50 mL/min adjusted for participant's body surface area using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI 2021) formula * Platelet count of \< 100 x 109/L * Absolute neutrophil count (ANC) \< 1.5 x 109/L * Hemoglobin \< 9 g/dL * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 3 x upper limit of normal (ULN), or \> 5 x ULN for participants with known liver metastases * Total bilirubin \> 1.5 x ULN, except for participants with documented Gilbert's syndrome who are eligible if total bilirubin ≤ 3 x ULN * For participants not taking warfarin or other anticoagulants: INR ≤1.5 or PT ≤1.5 x ULN; and either PTT or aPTT ≤1.5 x ULN. Participants ta
Conditions Anatomic Stage I Breast Cancer AJCC v8, ...
Phase PHASE2
Enrollment 75
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This phase II trial compares leuprolide to goserelin for reducing estrogen production by the ovaries in pre- or peri-menopausal women with breast cancer. Estrogen can cause the growth of breast cancer cells. Both leuprolide and goserelin lower the amount of estrogen made by the body. This may help stop the growth of tumor cells that need estrogen to grow. This study compares lower dose leuprolide, higher dose leuprolide, and goserelin for their ability to suppress the function of the ovaries to produce estrogen. Both doses of leuprolide may be as safe, tolerable and/or effective as goserelin in suppressing ovarian function in pre- or peri-menopausal women with breast cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Biospecimen Collection — Undergo blood sample collection
  • Other: Electronic Health Record Review — Ancillary studies
  • Drug: Goserelin — Given SC
  • Drug: Leuprolide — Given IM
  • Other: Questionnaire Administration — Ancillary studies

Primary Outcomes

  • Proportion of participants with ultrasensitive estradiol concentration > 10 pg/ml (During the first 24 weeks of therapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-01-22
Completion: 2028-01-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 75 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Michigan Rogel Cancer Center
Principal Investigators:
  • Norah L Henry (PRINCIPAL_INVESTIGATOR) - University of Michigan Rogel Cancer Center
Contact Information
Study Contact:
Cancer AnswerLine
1-800-865-1125
CancerAnswerLine@med.umich.edu
Cancer AnswerLine
800-865-1125
CancerAnswerLine@med.umich.edu
University of Michigan Comprehensive Cancer Center
Norah L. Henry
University of Michigan Comprehensive Cancer Center
Interventions
  • Procedure: Biospecimen Collection — Undergo blood sample collection
  • Other: Electronic Health Record Review — Ancillary studies
  • Drug: Goserelin — Given SC
  • Drug: Leuprolide — Given IM
  • Other: Questionnaire Administration — Ancillary studies
Study Locations (1 sites)
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 United States
Eligibility Criteria
Inclusion Criteria: * Female subject aged ≥ 18 years * Pre- or peri-menopausal patient, who had (1) menses either within the 12 months prior to or since breast cancer diagnosis or (2) estradiol concentration above the postmenopausal range per institutional laboratory guidance either within the 12 months prior to or since breast cancer diagnosis. * Planning to take GnRHa therapy in combination with oral endocrine therapy (tamoxifen, anastrozole, exemestane, or letrozole) for adjuvant treatment of stage 1-3 breast cancer or for treatment of metastatic breast cancer. Prior treatment with GnRHa therapy for treatment of non-oncologic conditions or during chemotherapy is permitted. * Not planning bilateral salpingo-oophorectomy during the 6-month study duration * Completion of chemotherapy, if given. Concurrent use of trastuzumab, pertuzumab, bisphosphonate therapy, poly adenosine diphosphate-ribose polymerase (PARP) inhibitor therapy, cyclin D kinase 4/6 (CDK4/6) inhibitor, and/or phosphoinositide 3-kinase (PI3K) inhibitor therapy is permitted * Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines Exclusion Criteria: * Prior bilateral salpingo-oophorectomy * Known to be pregnant or breastfeeding (negative pregnancy test will be confirmed prior to study treatment initiation) * Concomitant use of systemic or transdermal estrogen products * Known allergy or hypersensitivity to goserelin or leuprolide, or any of the excipients in the medications * Unable to take oral medications * Any medical condition that would interfere with the absorption of endocrine therapy. Prior gastric bypass is permitted * Patients with a prior or concurrent malignancy whose natural history or treatment, in the opinion of the treating investigator, has the potential to interfere with the safety or efficacy assessment of the investigational regimen
Conditions Advanced Breast Carcinoma, Anatomic Stag...
Phase Not Applicable
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluates the use of supportive care in patients with advanced breast cancer to better understand what has helped them, what has been hard, and what kind of help they still need.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Non-Interventional Study — Non-interventional study

Primary Outcomes

  • Acceptability of current LWABC (Living Well with Advanced Breast Cancer) model (Up to study completion, up to 1 day)
  • Participant medical history, treatment records, and demographic data (Up to study completion, up to 1 day)
  • Differences in survivorship care engagement across four distinct cohorts (Up to study completion, up to 1 day)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-01-13
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ohio State University Comprehensive Cancer Center
Collaborators: Lilly Foundation
Principal Investigators:
  • Ashley P Davenport, MD (PRINCIPAL_INVESTIGATOR) - Ohio State University Comprehensive Cancer Center
Contact Information
Study Contact:
The Ohio State University Comprehensive Cancer Center
800-293-5066
OSUCCCClinicaltrials@osumc.edu
Ashley P. Davenport, MD
614-366-8541
Ashley.Davenport@osumc.edu
Ohio State University Comprehensive Cancer Center
Ashley P. Davenport, MD
Ohio State University Comprehensive Cancer Center
Interventions
  • Other: Non-Interventional Study — Non-interventional study
Study Locations (1 sites)
Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210 United States
Eligibility Criteria
Inclusion Criteria: * \* COHORT 1: * Diagnosis of stage 4 metastatic breast cancer within the past 5 years * Never been referred to the LWABC * Adults age ≥ 18 years * COHORT 2: * Diagnosis of stage 4 metastatic breast cancer within the past 5 years * Have cancelled an appointment with the LWABC * Adults age ≥ 18 years * COHORT 3: * Been seen in the Medical Oncology Clinic at Stephanie Spielman Comprehensive Breast Center (SSCBC) within the past 5 years * Completed an appointment with the LWABC * Adults age ≥ 18 years * COHORT 4: * Caregivers for ABC patients * Adults age ≥ 18 years Exclusion Criteria: * Patients who cannot provide own informed consent
Conditions Open Angle Glaucoma, Pigmentary Glaucoma...
Phase PHASE4
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The Investigators will investigate the efficacy of combining the standalone iStent infinite and iDose that are minimally invasive surgical and drug depot options are a safe and effective alternative to filtering surgery for intraocuar pressure reduction in patients with medically uncontrolled open angle glaucoma.

Design

Study type: Interventional Phases: Phase4 Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Device: iStent infinite trabecular micro-bypass system model iS3 — surgery perfomed using the iStent infinite trabecular micro-bypass system model iS3
  • Drug: iDose TR (Travoprost intracameral Implant) 75mcg — surgery performed using the iDose TR (Travoprost intracameral Implant) 75mcg

Primary Outcomes

  • IOP reduction from baseline (Diurnal IOP reduction from baseline at 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2026-01-05
Completion: 2031-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jonathon Myers
Collaborators: Glaukos Corporation
Principal Investigators:
  • Dilru Amarasekera, MD (PRINCIPAL_INVESTIGATOR) - Wills Eye Hospital Glaucoma Research
Contact Information
Study Contact:
Meskerem Divers
215-825-4712
mdivers@willseye.org
Jeanne L Molineaux, COA
215-825-4713
jmolineaux@willseye.org
Meskerem Divers
(215)825-4712
mdivers@willseye.org
Wills Eye Hosital Glaucoma Dept.
Interventions
  • Device: iStent infinite trabecular micro-bypass system model iS3 — surgery perfomed using the iStent infinite trabecular micro-bypass system model iS3
  • Drug: iDose TR (Travoprost intracameral Implant) 75mcg — surgery performed using the iDose TR (Travoprost intracameral Implant) 75mcg
Study Locations (1 sites)
Wills Eye Hosital Glaucoma Dept., Philadelphia, Pennsylvania 19107 United States
Eligibility Criteria
Inclusion Criteria: * Moderate to severe open angle glaucoma (including POAG, PG, and PXG) * Open angle configuration (Shaffer grade ≥ 3), normal angle anatomy9 * Visual acuity HM or better * VF MD -6dB or worse * Failed medical therapy and/or laser treatment * Incisional glaucoma surgery contemplated as next intervention * Phakic or pseudophakic Exclusion Criteria: * Traumatic, uveitic, neovascular glaucoma, or angle closure glaucoma * Previous incisional glaucoma surgery * ALT; History of iridotomy, SLT, or micropulse laser trabeculoplasty within the prior 90 days * Active ocular inflammation or edema, clinically significant corneal dystrophy * Corneal or other pathology preventing accurate Goldmann applanation tonometry
Conditions Postpartum Preeclampsia
Phase NA
Enrollment 60
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to address the significant morbidity associated with preeclampsia diagnosed after delivery. All participants will undergo biomarker evaluation with soluble fms-like tyrosine kinase-1 and placental growth factor (sFlt-1/PlGF) ratio testing before delivery to assess the predictive ability of these biomarkers with new-onset postpartum preeclampsia. High-risk participants will be randomized to a bundle of care strategies aimed at early detection and management of postpartum preeclampsia.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Other: Early detection and management of postpartum preeclampsia bundle — Remote blood pressure monitoring, education, and dispensing antihypertensive medication (nifedipine ER) for outpatient management of asymptomatic, mild range BP.

Primary Outcomes

  • Study feasibility (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-03
Completion: 2027-06
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical College of Wisconsin
Collaborators: Dhulikhel Hospital
Principal Investigators:
  • Anna Palatnik, MD (PRINCIPAL_INVESTIGATOR) - Medical College of Wisconsin
Contact Information
Study Contact:
Alyssa Hernandez, DO
4148055285
alyhernandez@mcw.edu
Abha Shrestha, MD
0977-1-5522981
abhaobgy@kusms.edu.np
Dhulikhel Hospital
Abha Shrestha, MD
Dhulikhel Hospital
Interventions
  • Other: Early detection and management of postpartum preeclampsia bundle — Remote blood pressure monitoring, education, and dispensing antihypertensive medication (nifedipine ER) for outpatient management of asymptomatic, mild range BP.
Study Locations (2 sites)
Medical College of Wisconsin, Milwaukee, Wisconsin 53226 United States
Dhulikhel Hospital, Dhulikhel, Nepal
Eligibility Criteria
Inclusion Criteria: * Pregnant patients ≥ 36 weeks gestation without major fetal anomalies * Age ≥ 18 years * Admitted for labor at Dhulikhel Hospital, or intend to deliver at Dhulikhel Hospital * At risk for preeclampsia, using the Clinical Risk Assessment for Preeclampsia according to ACOG and USPSTF * 1 or more high risk factors: * History of preeclampsia * Type 1 or 2 diabetes * Multifetal gestation? * Renal disease * Autoimmune disease * 2 or more moderate risk factors: * Nulliparity * BMI \> 30 * First-degree relative with a history of preeclampsia * African American race * Low socioeconomic status * Age \> 35 years * History of low birthweight or small for gestational age * Previous adverse pregnancy outcome * Interpregnancy interval \> 10 years Exclusion Criteria: * Antenatal hypertensive disorder of pregnancy diagnosis, including gestational hypertension, preeclampsia, eclampsia, or HELLP syndrome, according to ACOG guidelines * Chronic hypertension, according to ACOG guidelines * Known allergy or contraindication to nifedipine * Inability or unwillingness to provide informed consent * Two or more blood pressures with an SBP ≥140 or DBP ≥90 after consent and prior to sFlt-1/PlGF testing (screen failure criteria)

SAINT in Postpartum Depression (PPD)

NCT07210255
Recruiting
Conditions Postpartum Depression (PPD)
Phase NA
Enrollment 192
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is a large, multi-site clinical trial testing whether Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), a fast-acting form of repetitive transcranial magnetic stimulation (rTMS), can more effectively reduce symptoms of postpartum depression (PPD) compared to a sham treatment. It will enroll 192 women within 12 months postpartum who are experiencing depression, and will track their progress for up to 12 months. The trial's main goal is to see if SAINT leads to reduction in depression severity in women with postpartum depression.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Device: SAINT Neuromodulation System — SAINT will be delivered via a MagPro X100 edition (MagVenture, Skovlunde, Denmark) TMS device equipped with a Cool-B65 A/P coil. The stimulation paradigm consists of 10 daily sessions (50 total sessions over 5 days) of SAINT stimulation (3-pulse 50-Hz bursts at 5-Hz for 2-second trains, with trains every 10 seconds), delivered with 50-minute inter-session intervals (10-minute sessions, 50-minutes in between sessions). Stimulation will be administered at 90% of the participant's resting motor threshold, with depth correction applied to adjust for the measured distance between the scalp and cortical surface. The stimulation target, the L-DLPFC, will be identified and localized by the study investigator using the Localite neuronavigation system.
  • Device: Sham SAINT Stimulation — Sham stimulation will be delivered using the MagVenture MagPro X100 TMS system with the Cool-B65 A/P coil and targeted to the L-DLPFC. The stimulation paradigm will be identical to the active SAINT stimulation with the exception that active stimulation will not be delivered.

Primary Outcomes

  • The change in depression symptom severity, assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS), from baseline to 5 days post-treatment, which will be compared between the acute active SAINT and sham arms. (Baseline and 5 days post-acute treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-01
Completion: 2029-10-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 192 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Magnus Medical
Collaborators: Congressionally Directed Medical Research Programs
Contact Information
Study Contact:
Erin Hanzlik
774.370.8613
erin.hanzlik@umassmemorial.org
UMass Chan Medical School
Sherry Stumpo
508-334-1055
sherry.stumpo@umassmed.edu
UMass Chan Medical School
Kimberly Yonkers, MD
UMass Chan Medical School
Interventions
  • Device: SAINT Neuromodulation System — SAINT will be delivered via a MagPro X100 edition (MagVenture, Skovlunde, Denmark) TMS device equipped with a Cool-B65 A/P coil. The stimulation paradigm consists of 10 daily sessions (50 total sessions over 5 days) of SAINT stimulation (3-pulse 50-Hz bursts at 5-Hz for 2-second trains, with trains every 10 seconds), delivered with 50-minute inter-session intervals (10-minute sessions, 50-minutes in between sessions). Stimulation will be administered at 90% of the participant's resting motor threshold, with depth correction applied to adjust for the measured distance between the scalp and cortical surface. The stimulation target, the L-DLPFC, will be identified and localized by the study investigator using the Localite neuronavigation system.
  • Device: Sham SAINT Stimulation — Sham stimulation will be delivered using the MagVenture MagPro X100 TMS system with the Cool-B65 A/P coil and targeted to the L-DLPFC. The stimulation paradigm will be identical to the active SAINT stimulation with the exception that active stimulation will not be delivered.
Study Locations (4 sites)
UMass Chan Medical School, Worcester, Massachusetts 01655 United States
Icahn School of Medicine at Mount Sinai, New York, New York 10029 United States
The Medical University of South Carolina (MUSC), Charleston, South Carolina 29425 United States
University of Texas at Austin, Dell Medical School, Health Discovery Building, Austin, Texas 78712 United States
Eligibility Criteria
Inclusion Criteria: 1. Reproductive Women ages 18-45 at the time of consent. 2. Diagnosis of non-psychotic Major Depressive Episode (MDE) with peripartum onset as assessed through the Quick Structured Clinical Interview for DSM-5. 3. 0-12 months postpartum. Participants must be 0-12 months postpartum at screening and remain within 12 months postpartum at the 5-day post-treatment visit. 4. If currently taking an antidepressant medication and/or receiving psychotherapy must be on a stable regimen for 30 days at the time of enrollment. 5. Severe depression as measured by MADRS ≥20 at screening. 6. A good candidate for repetitive transcranial magnetic stimulation (rTMS) as determined by a physician. 7. Participants must be capable of giving informed consent. Participants must be proficient in English in order to comprehend study requirements. 8. Agree to use effective contraception in the postpartum period for the study duration. 9. Willing and able to comply with all study procedures, complete required assessments and visits, and be available for the duration of the study. Exclusion Criteria: 1. Participant has attempted suicide in the last 6 months and/or expressed suicidal ideation with intent as determined by physician assessment at the time of enrollment. 2. Score of 6 on MADRS item 10 (high rating of suicidal ideation) at screening. 3. Participant has active psychosis per investigator assessment. 4. Participant with a primary lifetime diagnosis of bipolar disorder, schizophrenia, schizoaffective disorder and/or obsessive-compulsive disorder. 5. Participant has an active eating disorder or substance use disorder in the past 6 months and/or has a positive urine toxicity screen that the Principal Investigator (PI) deems exclusionary. 6. Participant is using any exclusionary medications: high dose of benzodiazepines (\>2mg lorazepam daily equivalent and/or \>3 times per week) or medications that would interfere with treatment with TMS as per PI or designee discretion. 7. Participant has a history of untreated or insufficiently treated sleep apnea. 8. Participant has a history of significant neurologic disease, including developmental disability, dementia, Parkinson's or Huntington's disease, brain tumor, unexpected seizure/epilepsy disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma. 9. Any untreated major somatic illness such as hypertension/cardiovascular disease/diabetes/endocrine disorders etc. 10. Contraindications to receiving rTMS (e.g., metal in head, history of seizure, known brain lesion). 11. Contraindications to MRI (e.g., ferromagnetic metal in their body). 12. Currently pregnant. 13. History of receiving rTMS for any reason, as this may compromise blinding.
Conditions Major Depressive Disorder
Phase NA
Enrollment 145
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to improve depression treatment by establishing reliable prefrontal excitability markers through Targeting with Automated Real-time Guidance for Enhancing TEPs (TARGET).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Triple

Interventions / Regimen

  • Device: Active Single-Pulse TMS — Single-pulse transcranial magnetic stimulation is delivered to the left dorsolateral prefrontal cortex using a MagVenture X100 stimulator and B65 A/P coil across predefined locations, coil angles, and stimulation intensities.
  • Device: Sham Single-Pulse TMS — Sham single-pulse TMS is delivered using a flipped coil and concurrent scalp electrical stimulation to mimic auditory and somatosensory sensations without producing cortical stimulation.
  • Device: TARGET-optimized TMS — Single-pulse TMS parameters (location, angle, and intensity) are adjusted in real time using the TARGET closed-loop algorithm based on concurrent EEG measurements to deliver optimized stimulation.
  • Device: Non-optimized (Open-Loop) TMS — Single-pulse TMS is delivered using a predefined open-loop set of stimulation parameter combinations across multiple dlPFC locations, coil angles, and intensities without real-time adjustment.
  • Other: EEG Recording — Participants undergo concurrent 64-channel TMS-compatible scalp EEG recording during stimulation to measure TMS-evoked neural responses.
  • Other: Intracranial EEG (iEEG) Recording — Neurosurgical participants undergo intracranial EEG recording using clinically implanted electrodes during TMS to measure local and downstream neural activity.

Primary Outcomes

  • Changes in Anterior EL-TEP Amplitude after single-pulse TMS (spTMS) (Baseline, end of spTMS (6 hours))
  • Changes in Posterior EL-TEP Amplitude after spTMS (Baseline, end of spTMS (6 hours))
  • Changes in intracranial TMS-Evoked Potential (iTEP) Amplitude after TMS-iEEG (Baseline, end of spTMS (20 minutes))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-23
Completion: 2029-11-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 145 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Stanford University
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Corey J Keller, MD, PhD (PRINCIPAL_INVESTIGATOR) - Stanford University
Contact Information
Study Contact:
Jade T Truong, BS
408-840-3313
kellerlab@stanford.edu
Jade T Truong, BS
408-840-3313
kellerlab@stanford.edu
University of Iowa
Aaron D Boes, MD, PhD
University of Iowa
Interventions
  • Device: Active Single-Pulse TMS — Single-pulse transcranial magnetic stimulation is delivered to the left dorsolateral prefrontal cortex using a MagVenture X100 stimulator and B65 A/P coil across predefined locations, coil angles, and stimulation intensities.
  • Device: Sham Single-Pulse TMS — Sham single-pulse TMS is delivered using a flipped coil and concurrent scalp electrical stimulation to mimic auditory and somatosensory sensations without producing cortical stimulation.
  • Device: TARGET-optimized TMS — Single-pulse TMS parameters (location, angle, and intensity) are adjusted in real time using the TARGET closed-loop algorithm based on concurrent EEG measurements to deliver optimized stimulation.
  • Device: Non-optimized (Open-Loop) TMS — Single-pulse TMS is delivered using a predefined open-loop set of stimulation parameter combinations across multiple dlPFC locations, coil angles, and intensities without real-time adjustment.
  • Other: EEG Recording — Participants undergo concurrent 64-channel TMS-compatible scalp EEG recording during stimulation to measure TMS-evoked neural responses.
Study Locations (2 sites)
University of Iowa, Iowa City, California 52246 United States
Stanford University, Stanford, California 94305 United States
Eligibility Criteria
Inclusion Criteria: * Men and women, ages 18 to 65 * Diagnosis of major depressive disorder, assessed through a Structured Clinical Interview for DSM-5 (SCID-5) * In a current depressive episode, assessed through a Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (SCID-5) * Moderate-to-severe depression as indicated by a score between 11-20 on the Quick Inventory of Depressive Symptoms (QIDS) * Must comprehend English well to ensure adequate comprehension of the EEG and TMS instructions, and of clinical scales * No current or history of neurological disorders * No seizure disorder or risk of seizures * Neurosurgical patients: Men and women ages 18-65 with medication-refractory epilepsy who are admitted for phase II intracranial monitoring to detect a seizure focus will be considered appropriate for this study. Participants must have the intellectual capacity to understand the consent process and agree to the study. Exclusion Criteria: * Those with a contraindication for MRIs (e.g. implanted metal) * History of head trauma with loss of consciousness * History of seizures or on medications that reduce seizure threshold (e.g., olanzapine, chlorpromazine, lithium) * Neurological or uncontrolled medical disease * Any unstable medical condition * Active substance abuse * Diagnosis of psychotic or bipolar disorder * A prior history of Electroconvulsive Therapy (ECT) failure * History of suicide attempt in the past year * Currently pregnant or breastfeeding * Repetitive Transcranial Magnetic Stimulation (rTMS) treatment in the past six months
Conditions Advanced Breast Cancer
Phase Not Applicable
Enrollment 118
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To evaluate the efficacy and safety of trastuzumab deruxtecan in advanced breast cancer patients.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: Trastuzumab deruxtecan — Trastuzumab deruxtecan is a combination of the targeted cancer drug trastuzumab (also known as Herceptin) and a chemotherapy drug called deruxtecan or DXd.

Primary Outcomes

  • Progression-Free Survival (PFS) (From the date of starting Disitamab vedotin to the date of first documentation of progression or death (up to approximately 1 years))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-08-28
Completion: 2029-02
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 118 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Wenjin Yin
Principal Investigators:
  • Wenjin Yin, M.D. (PRINCIPAL_INVESTIGATOR) - Renji Hospital,School of Medicine, Shanghai Jiaotong University
Contact Information
Study Contact:
Wenjin Yin, M.D.
86(21)68385569
yinwenjin@renji.com
Wenjin Yin
86(21)68385569
yinwenjin@renji.com
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Interventions
  • Drug: Trastuzumab deruxtecan — Trastuzumab deruxtecan is a combination of the targeted cancer drug trastuzumab (also known as Herceptin) and a chemotherapy drug called deruxtecan or DXd.
Study Locations (1 sites)
Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127 China
Eligibility Criteria
Inclusion Criteria: * Aged ≥18 and older * Breast cancer patients meeting current guideline recommendations and planning to receive trastuzumab deruxtecan * ECOG 0-1 Exclusion Criteria: * During pregnancy and lactation
Conditions Hypertension (HTN)
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This randomized clinical trial aims to compare two cardiorespiratory exercise training protocols - Sprint Interval Training (SIT), characterized by short, maximal-intensity efforts, versus Moderate-Intensity Continuous Training (MICT) - in patients with arterial hypertension. The primary objective is to evaluate the impact of both interventions on 24-hour ambulatory systolic blood pressure (ABPM) after a 12-week training period. Secondary outcomes include diastolic, daytime, and nighttime blood pressure, metabolic and hemodynamic parameters, body composition, and serum myokine levels (IL-6 and α-CGRP). Participants aged 30-59 years with diagnosed hypertension but without high cardiovascular risk will be recruited from the Cardio-Metabolic Disease Unit of Hospital San Martín (La Plata, Argentina). After a two-week familiarization period, eligible participants will be randomized to SIT or MICT groups. The intervention will last 12 weeks, with three supervised sessions per week. The study will provide valuable information about the effectiveness, safety, and clinical applicability of brief, high-intensity exercise for blood pressure control in hypertensive patients.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: SIT group: 2-4 maximal 20-30-second cycling sprints (≥100% VO₂max) with recovery intervals (2-4 min), total duration ≤15 minutes per session. — SIT group: 2-4 maximal 20-30-second cycling sprints (≥100% VO₂max) with recovery intervals (2-4 min), total duration ≤15 minutes per session. Three times per week for 12 weeks
  • Behavioral: MICT group: Continuous cycling at 50-70% of VO₂max, 15-30 minutes per session. — MICT group: Continuous cycling at 50-70% of VO₂max, 15-30 minutes per session. three times per week for 12 week

Primary Outcomes

  • To evaluate the differences between both exercise protocols in 24-hour systolic ambulatory blood pressure (ABPM) values after the 12-week programmed exercise (after the 12-week programmed exercise)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-29
Completion: 2027-01
Eligibility
Age: 30 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Unidad Enfermedades Cardiometabolicas- Hospital Interzonal General Agudos San Martin de La Plata
Principal Investigators:
  • Walter Espeche (PRINCIPAL_INVESTIGATOR) - Hospital Interzonal General San Martin
  • Julian Minetto, Physican (PRINCIPAL_INVESTIGATOR) - Hospital interzonal general agudos San Martin de La Plata
  • Matias Santamaria (PRINCIPAL_INVESTIGATOR) - Hospital interzonal general agudos San Martin de La Plata
Contact Information
Study Contact:
Julian Minetto, Physican
+542214835429
jjminetto@hotmail.com
Walter Espeche, Doctor (PH)
wespeche@gmail.com
Julian Minetto
+54 (221) 483-5429
jjminetto@hotmail.com
Hospital Interzonal General San Martin La Plata
Interventions
  • Behavioral: SIT group: 2-4 maximal 20-30-second cycling sprints (≥100% VO₂max) with recovery intervals (2-4 min), total duration ≤15 minutes per session. — SIT group: 2-4 maximal 20-30-second cycling sprints (≥100% VO₂max) with recovery intervals (2-4 min), total duration ≤15 minutes per session. Three times per week for 12 weeks
  • Behavioral: MICT group: Continuous cycling at 50-70% of VO₂max, 15-30 minutes per session. — MICT group: Continuous cycling at 50-70% of VO₂max, 15-30 minutes per session. three times per week for 12 week
Study Locations (1 sites)
Hospital Interzonal General San Martin La Plata, La Plata, Buenos Aires 1900 Argentina
Eligibility Criteria
Inclusion Criteria: * Patients of both sexes between 30-59 years of age who meet the definition of hypertension. Hypertension will be defined as: 1. Those patients who report a history of hypertension and are under pharmacological treatment for it (Angiotensin Converting Enzyme Inhibitors/Angiotensin II Receptor Antagonists/Calcium Channel Blockers/Thiazide Diuretics/Beta Blockers) at the time of the evaluation. OR 2. Patients who report a history of hypertension during the evaluation and who, without pharmacological treatment, have average levels ≥140/90 mmHg will also be considered hypertensive. Exclusion Criteria: * Extreme body mass index (BMI) \<18.5 and ≥35. * Patients with office blood pressure readings ≥160/100 mmHg. * Patients with high cardiovascular risk conditions such as type II diabetes, chronic kidney disease (\<60 milliseconds), history of cerebrovascular disease, coronary artery disease, peripheral arterial disease, or heart failure (Framingham Criteria clinical diagnosis). * Pregnant or postpartum women up to 3 months old. * Patients with psychophysical limitations that make exercise difficult. * Patients with a history of active malignant neoplastic disease under treatment. Elimination Criteria -Patients whose pharmacological treatment is initiated or modified during the follow-up after 3 months.
Conditions Breast Cancer, Neoadjuvant Therapy, Path...
Phase Not Applicable
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This prospective observational study aims to investigate subtype-specific circulating microRNAs (miRNAs) and their association with response to neoadjuvant chemotherapy (NAC) in patients with breast cancer. Serum samples will be collected before NAC and prior to surgery, and changes in miRNA expression levels will be evaluated. Pathological complete response (pCR) and Miller-Payne scoring will be used to assess treatment response after NAC. The study also explores whether changes in circulating miRNA profiles can predict treatment response across different breast cancer subtypes. The findings may help identify biomarkers that support treatment planning and personalized therapy strategies.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Change in circulating microRNA expression levels before and after neoadjuvant chemotherapy (Baseline (before NAC) and pre-surgery (after completion of NAC))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-12-15
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Atlas University
Principal Investigators:
  • Emine Yildirim, MD (PRINCIPAL_INVESTIGATOR) - Atlas University Faculty of Medicine
Contact Information
Study Contact:
Emine Yildirim, MD
+905056234825
opdreyildirim@gmail.com
Interventions
N/A
Study Locations (1 sites)
Istanbul Atlas University Faculty of Medicine, Istanbul, Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed breast cancer * Planned to receive neoadjuvant chemotherapy * Biologically female * Age ≥ 18 years * Ability to provide informed consent * Adequate organ function to receive standard NAC (based on routine clinical evaluation) Exclusion Criteria: * Presence of metastatic disease at diagnosis * Prior systemic chemotherapy for breast cancer * Pregnancy or breastfeeding * Active infection or uncontrolled comorbid conditions interfering with study participation * Any condition preventing collection of blood samples